Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule. (scientific article)

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

Q24646237

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

Q24676203

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathwa

Q40641241

Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.

Q40642281

Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation

Q42839185

Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells

Q43005361

Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.

Q46047974

An optimized method for measurement of gamma-H2AX in blood mononuclear and cultured cells

Q46502653

Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma

Q46902067

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

Q51803667

Effect of electric field pulses on the viability and on the membrane-bound immunoglobulins of LPS-activated murine B-lymphocytes: correlation with the cell cycle

Q72374665

Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis

Q73034239

Integration of EGFR inhibitors with radiochemotherapy

Q79227019

Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature

Q82638153

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Q27860910

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

Q28131715

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment

Q28188301

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils

Q28480417

The protein kinase B/Akt signalling pathway in human malignancy

Q28645742

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

Q29547860

The TOR pathway: a target for cancer therapy

Q29614242

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Q29618117

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

Q33453675

Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study

Q33477348

The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo

Q33939369

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma

Q34001234

Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage

Q34161001

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance

Q34447846

Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s)

Q34972742

The mTOR inhibitor rapamycin suppresses DNA double-strand break repair

Q35545852

The role of p53 in chemosensitivity and radiosensitivity.

Q35567279

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

Q35581650

Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs

Q35640098

The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses

Q35763894

Normal expression of DNA repair proteins, hMre11, Rad50 and Rad51 but protracted formation of Rad50 containing foci in X-irradiated skin fibroblasts from radiosensitive cancer patients

Q36694318

Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy

Q37212251

Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations

Q37382669

Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells

Q37395564

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity

Q39373143

Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells

Q39456285

Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation

Q39504308

The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation

Q39631233

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

Q39650704

NVP-BEZ235 as a new therapeutic option for sarcomas.

Q39752874

mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling

Q39765614

Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility

Q39804812

Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism

Q40357398

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

glioblastoma

Q282142

P304

page(s)

169-179

P577

publication date

2013-04-01

P1433

published in

Translational Oncology

Q26839583

P1476

title

Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule

P478

volume

Reverse relations

cites work (P2860)

Q35677134	A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy
Q26849503	A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy
Q38963519	Actin cytoskeleton organization, cell surface modification and invasion rate of 5 glioblastoma cell lines differing in PTEN and p53 status.
Q47093662	Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment
Q39027066	Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status
Q45840119	Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor
Q42363700	Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule
Q89834264	Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Due to Suppressed Double-Strand Break (DSB) Repair by Non-Homologous End Joining
Q92276299	Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
Q55689566	Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer.
Q36192506	Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non-small-cell Lung Cancer
Q34677991	Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody
Q37415954	Glioblastoma multiforme therapy and mechanisms of resistance.
Q36128222	Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress
Q99238268	Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting
Q38172298	Isogenic radiation resistant cell lines: development and validation strategies.
Q34251033	KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis
Q64262900	MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo
Q36918102	MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Q37709001	MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma
Q38936710	Novel Approaches to Apoptosis-Inducing Therapies
Q37660260	Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.
Q38720885	Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy
Q38431453	Radiation therapy for glioma stem cells
Q36069410	Rapamycin-induced autophagy sensitizes A549 cells to radiation associated with DNA damage repair inhibition
Q33776641	Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
Q60929534	Removal of heat-sensitive clustered damaged DNA sites is independent of double-strand break repair
Q38825141	Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization
Q61805942	Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response